229 related articles for article (PubMed ID: 30793281)
1. Immunohistochemical predictive markers of response to conservative treatment of endometrial hyperplasia and early endometrial cancer: A systematic review.
Travaglino A; Raffone A; Saccone G; Insabato L; Mollo A; De Placido G; Zullo F
Acta Obstet Gynecol Scand; 2019 Sep; 98(9):1086-1099. PubMed ID: 30793281
[TBL] [Abstract][Full Text] [Related]
2. PTEN as a predictive marker of response to conservative treatment in endometrial hyperplasia and early endometrial cancer. A systematic review and meta-analysis.
Travaglino A; Raffone A; Saccone G; Insabato L; Mollo A; De Placido G; Zullo F
Eur J Obstet Gynecol Reprod Biol; 2018 Dec; 231():104-110. PubMed ID: 30342311
[TBL] [Abstract][Full Text] [Related]
3. Should progesterone and estrogen receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis.
Raffone A; Travaglino A; Saccone G; Mollo A; De Placido G; Insabato L; Zullo F
Acta Obstet Gynecol Scand; 2019 Aug; 98(8):976-987. PubMed ID: 30779338
[TBL] [Abstract][Full Text] [Related]
4. [Outcome analysis of conservative treatment of well-differentiated endometrial adenocarcinoma and severe atypical hyperplasia in young women].
Yu M; Shen K; Yang JX; Huang HF; Wu M; Pan LY; Lang JH; Lian LJ
Zhonghua Fu Chan Ke Za Zhi; 2006 Apr; 41(4):242-5. PubMed ID: 16759458
[TBL] [Abstract][Full Text] [Related]
5. Fertility-Sparing Approach in Patients with Endometrioid Endometrial Cancer Grade 2 Stage IA (FIGO): A Qualitative Systematic Review.
Giampaolino P; Cafasso V; Boccia D; Ascione M; Mercorio A; Viciglione F; Palumbo M; Serafino P; Buonfantino C; De Angelis MC; Verrazzo P; Grasso G; Gullo G; Bifulco G; Della Corte L
Biomed Res Int; 2022; 2022():4070368. PubMed ID: 36203482
[TBL] [Abstract][Full Text] [Related]
6. Loss of PTEN expression as diagnostic marker of endometrial precancer: A systematic review and meta-analysis.
Raffone A; Travaglino A; Saccone G; Campanino MR; Mollo A; De Placido G; Insabato L; Zullo F
Acta Obstet Gynecol Scand; 2019 Mar; 98(3):275-286. PubMed ID: 30511743
[TBL] [Abstract][Full Text] [Related]
7. The fertility-sparing treatment in patients with endometrial atypical hyperplasia and early endometrial cancer: a debated therapeutic option.
Gadducci A; Spirito N; Baroni E; Tana R; Genazzani AR
Gynecol Endocrinol; 2009 Oct; 25(10):683-91. PubMed ID: 19562604
[TBL] [Abstract][Full Text] [Related]
8. Combined phospho-Akt and PTEN expressions associated with post-treatment hysterectomy after conservative progestin therapy in complex atypical hyperplasia and stage Ia, G1 adenocarcinoma of the endometrium.
Minaguchi T; Nakagawa S; Takazawa Y; Nei T; Horie K; Fujiwara T; Osuga Y; Yasugi T; Kugu K; Yano T; Yoshikawa H; Taketani Y
Cancer Lett; 2007 Apr; 248(1):112-22. PubMed ID: 16919866
[TBL] [Abstract][Full Text] [Related]
9. Dual-specificity phosphatase 6 predicts the sensitivity of progestin therapy for atypical endometrial hyperplasia.
Zhang H; Yan L; Bai Y; Li C; Guo Q; Wang C; Zhao X; Li M
Gynecol Oncol; 2015 Mar; 136(3):549-53. PubMed ID: 25451692
[TBL] [Abstract][Full Text] [Related]
10. Increased natural killer cells and decreased regulatory T cells are seen in complex atypical endometrial hyperplasia and well-differentiated carcinoma treated with progestins.
Witkiewicz AK; McConnell T; Potoczek M; Emmons RV; Kurman RJ
Hum Pathol; 2010 Jan; 41(1):26-32. PubMed ID: 19733383
[TBL] [Abstract][Full Text] [Related]
11. PTEN expression in endometrial hyperplasia and risk of cancer: a systematic review and meta-analysis.
Raffone A; Travaglino A; Saccone G; Viggiani M; Giampaolino P; Insabato L; Mollo A; De Placido G; Zullo F
Arch Gynecol Obstet; 2019 Jun; 299(6):1511-1524. PubMed ID: 30915635
[TBL] [Abstract][Full Text] [Related]
12. Relapse of endometrial hyperplasia after conservative treatment: a cohort study with long-term follow-up.
Gallos ID; Krishan P; Shehmar M; Ganesan R; Gupta JK
Hum Reprod; 2013 May; 28(5):1231-6. PubMed ID: 23466671
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms involved in the evolution of progestin resistance in human endometrial hyperplasia--precursor of endometrial cancer.
Wang S; Pudney J; Song J; Mor G; Schwartz PE; Zheng W
Gynecol Oncol; 2003 Feb; 88(2):108-17. PubMed ID: 12586588
[TBL] [Abstract][Full Text] [Related]
14. Prediction of Relapse After Therapy Withdrawal in Women with Endometrial Hyperplasia: A Long-term Follow-up Study.
Sletten ET; Arnes M; Lysa LM; Moe BT; Straume B; Orbo A
Anticancer Res; 2017 May; 37(5):2529-2536. PubMed ID: 28476823
[TBL] [Abstract][Full Text] [Related]
15. Abnormal mismatch repair and other clinicopathologic predictors of poor response to progestin treatment in young women with endometrial complex atypical hyperplasia and well-differentiated endometrial adenocarcinoma: a consecutive case series.
Zakhour M; Cohen JG; Gibson A; Walts AE; Karimian B; Baltayan A; Aoyama C; Garcia L; Dhaliwal SK; Elashoff D; Amneus M; Walsh C
BJOG; 2017 Sep; 124(10):1576-1583. PubMed ID: 28128512
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices.
Reyes HD; Carlson MJ; Devor EJ; Zhang Y; Thiel KW; Samuelson MI; McDonald M; Yang S; Stephan JM; Savage EC; Dai D; Goodheart MJ; Leslie KK
Gynecol Oncol; 2016 Jan; 140(1):152-60. PubMed ID: 26524723
[TBL] [Abstract][Full Text] [Related]
17. Mismatch repair-deficiency specifically predicts recurrence of atypical endometrial hyperplasia and early endometrial carcinoma after conservative treatment: A multi-center study.
Raffone A; Catena U; Travaglino A; Masciullo V; Spadola S; Della Corte L; Piermattei A; Insabato L; Zannoni GF; Scambia G; Zullo F; Bifulco G; Fanfani F; Di Spiezio Sardo A
Gynecol Oncol; 2021 Jun; 161(3):795-801. PubMed ID: 33812697
[TBL] [Abstract][Full Text] [Related]
18. Improving response to progestin treatment of low-grade endometrial cancer.
Baxter E; Brennan DJ; McAlpine JN; Mueller JJ; Amant F; van Gent MDJM; Huntsman DG; Coleman RL; Westin SN; Yates MS; Krakstad C; Quinn MA; Janda M; Obermair A
Int J Gynecol Cancer; 2020 Nov; 30(11):1811-1823. PubMed ID: 32381512
[TBL] [Abstract][Full Text] [Related]
19. Fertility-Sparing Treatment of Early Endometrial Cancer and Complex Atypical Hyperplasia in Young Women of Childbearing Potential.
Pronin SM; Novikova OV; Andreeva JY; Novikova EG
Int J Gynecol Cancer; 2015 Jul; 25(6):1010-4. PubMed ID: 25950126
[TBL] [Abstract][Full Text] [Related]
20. Dusp6 immunohistochemistry is associated with the response of atypical endometrial hyperplasia and early endometrial cancer to conservative treatment.
Travaglino A; Raffone A; Gencarelli A; Micheli M; Franco L; Zullo F; Mollo A; Di Spiezio Sardo A; Bifulco G; Insabato L
Int J Gynaecol Obstet; 2022 Sep; 158(3):742-747. PubMed ID: 34837386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
